Results 11 to 20 of about 74,294 (341)
HemaSphere, 2022 Resistance to cytarabine is a key problem in the treatment of acute myeloid leukemia (AML). To understand the molecular biology of resistance to cytarabine, a viability-based chemosensitizer screen was utilized. We screened synthetic lethal targets using
Miriam Rehberger +7 more
doaj +1 more source
Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia
Nature Communications, 2022 Devimistat is a TCA cycle inhibitor. A previously completed phase I study of devimistat in combination with cytarabine and mitoxantrone in patients with relapsed or refractory AML showed promising response rates.
Rebecca G. Anderson +13 more
semanticscholar +1 more source
Cancers, 2021 Simple Summary In this review, the authors propose a crosswise examination of cytarabine-related issues ranging from the spectrum of clinical activity and severe toxicities, through updated cellular pharmacology and drug formulations, to the genetic ...
R. Di Francia +10 more
semanticscholar +1 more source
The polo-like kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia [PDF]
, 2013 CD56 is expressed in 15–20% of acute myeloid leukaemias (AML) and is associated with extramedullary diffusion, multidrug resistance and poor prognosis.
A Blair +55 more
core +5 more sources
Gels, 2022 In the current study, a pH sensitive intelligent hydroxypropyl–β–cyclodextrin-based polymeric network (HP-β-CD-g-MAA) was developed through a solution polymerization technique for site specific delivery of cytarabine in the colonic region.
Nighat Batool +7 more
doaj +1 more source
Blood Cancer Discovery, 2021 Immune suppression, exhaustion, and senescence are frequently seen throughout disease progression in acute myeloid leukemia (AML). We conducted a phase II study of high-dose cytarabine followed by pembrolizumab 200 mg i.v. on day 14 to examine whether PD-
J. Zeidner +21 more
semanticscholar +1 more source
Orphanet Journal of Rare Diseases, 2022 Background Non-Langerhans cell histiocytosis, including Erdheim–Chester disease (ECD), Rosai–Dorfman disease (RDD), indeterminate cell histiocytosis (ICH), and unclassified histiocytosis, is a rare disorder lacking a standard treatment strategy.
Ting Liu +7 more
doaj +1 more source
Brain and Behavior, Volume 12, Issue 12, December 2022., 2022 Abstract Objective Childhood cancer and cancer‐related treatments disrupt brain development and maturation, placing survivors at risk for cognitive late effects. Given that assessment tools vary widely across researchers and clinicians, it has been daunting to identify distinct patterns in outcomes across diverse cancer types and to implement ...
Julie A. Trapani, Donna L. Murdaugh
wiley +1 more source
Frontiers in Oncology, 2020 Background: The role of cytarabine on newly diagnosed primary central nervous system lymphoma (PCNSL) remains controversial. The present study mainly aimed to assess the efficacy and safety of cytarabine in the induction treatment of PCNSL.Methods: We ...
Xiaohong Zheng +4 more
doaj +1 more source
Iatreia, 2022 Knowledge about cytarabine induced cardiotoxicity is scarce. We present the clinical case of a 51-year-old patient with past medical history of Acute Myeloid Leukemia managed with high doses of cytarabine and who developed acute myopericarditis as a ...
Villa-Saldarriaga, María P +3 more
doaj +1 more source